dc.creatorSavoia, Anna
dc.creatorde Rocco, Daniela
dc.creatorPanza, Emanuele
dc.creatorBozzi, Valeria
dc.creatorScandellari, Raffaella
dc.creatorLoffredo, Giuseppe
dc.creatorMumford, Andrew
dc.creatorHeller, Paula Graciela
dc.creatorNoris, Patrizia
dc.creatorde Groot, Marco R.
dc.creatorGiani, Marisa
dc.creatorFreddi, Paolo
dc.creatorScognamiglio, Francesca
dc.creatorRiondino, Silvia
dc.creatorPujol Moix, Núria
dc.creatorFabris, Fabrizio
dc.creatorSeri, Marco
dc.creatorBalduini, Carlo L.
dc.creatorPecci, Alessandro
dc.date.accessioned2017-04-20T20:56:31Z
dc.date.accessioned2018-11-06T15:54:04Z
dc.date.available2017-04-20T20:56:31Z
dc.date.available2018-11-06T15:54:04Z
dc.date.created2017-04-20T20:56:31Z
dc.date.issued2010-03
dc.identifierSavoia, Anna; de Rocco, Daniela; Panza, Emanuele; Bozzi, Valeria; Scandellari, Raffaella; et al.; Heavy chain myosin 9-related disease (MYH9-RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder; Schattauer Gmbh-verlag Medizin Naturwissenschaften; Thrombosis And Haemostasis; 103; 4; 3-2010; 683-873
dc.identifier0340-6245
dc.identifierhttp://hdl.handle.net/11336/15532
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1902304
dc.description.abstractMYH9 -related disease ( MYH9 -RD) is an autosomal dominant thrombocytopenia with giant platelets variably associated with young-adult onset of progressive sensorineural hearing loss, presenile cataract, and renal damage. MYH9 -RD is caused by mutations of MYH9 , the gene encoding for non-muscle heavy-chain myosin-9. Wild-type and mutant myosin-9 aggregate as cytoplasmic inclusions in patients’ leukocytes, the identification of which by immunofluorescence has been proposed as a suitable tool for the diagnosis of MYH9 -RD. Since the predictive value of this assay, in terms of sensitivity and specificity, is unknown, we investigated 118 consecutive unrelated patients with a clinical presentation strongly consistent with MYH9 -RD. All patients prospectively underwent both the immunofluorescence assay for myosin-9 aggregate detection and molecular genetic analysis of the MYH9 gene. Myosin-9 aggregates were identified in 82 patients, 80 of which (98%) had also a MYH9 mutation. In the remaining 36 patients neither myosin-9 aggregates nor MYH9 mutations were found. Sensitivity and specificity of the immunofluorescence assay was evaluated to be 100% and 95%, respectively. Except for the presence of aggregates, we did not find any other significant difference between patients with or without aggregates, demonstrating that the myosin-9 inclusions in neutrophils are a pathognomonic sign of the disease. However, the identification of the specific MYH9 mutation is still of importance for prognostic aspects of MYH9 -RD.
dc.languageeng
dc.publisherSchattauer Gmbh-verlag Medizin Naturwissenschaften
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1160/TH09-08-0593
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://th.schattauer.de/contents/archive/issue/1059/manuscript/12714.html
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectMYH9-related diseases
dc.subjectThrombocytopenia
dc.subjectGiant platelets
dc.subjectMYH9 gene
dc.subjectNeutrophil inclusions
dc.titleHeavy chain myosin 9-related disease (MYH9-RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder
dc.typeArtículos de revistas
dc.typeArtículos de revistas
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución